Tempest Therapeutics (TPST) said Thursday that the mid-stage clinical trial of TPST-1495 for the treatment of familial adenomatous polyposis has received a "study may proceed" letter from the US Food and Drug Administration.
The clinical-stage company said the Cancer Prevention Clinical Trials Network will run the mid-stage study, which will start this year and funded by the National Cancer Institute Division of Cancer Prevention.
Shares of the company were up more than 1% in recent premarket activity on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。